Yasuto Akiyama

Summary

Affiliation: Shizuoka Cancer Center
Country: Japan

Publications

  1. ncbi α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    BMC Cancer 12:623. 2012
  2. ncbi Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka, 411 8777, Japan
    Cancer Immunol Immunother 61:2311-9. 2012
  3. ncbi Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Sunto gun, Shizuoka, Japan
    Oncol Rep 22:185-91. 2009
  4. ncbi Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Anticancer Res 29:647-55. 2009
  5. ncbi Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Int J Oncol 33:433-41. 2008
  6. ncbi Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer
    Yasuto Akiyama
    National Cancer Center Research Institute, Growth Factor Division, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104, Japan
    Immunol Lett 95:199-205. 2004
  7. ncbi Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail
    Yasuto Akiyama
    Growth Factor Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104, Japan
    Anticancer Res 24:571-7. 2004
  8. ncbi Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
    Chie Oshita
    Division of Immunotherapy, Shizuoka Cancer Center Research Institute, Shizuoka 411 8777, Japan
    Oncol Rep 28:1131-8. 2012
  9. ncbi Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients
    Akira Iizuka
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Immunol Lett 135:64-73. 2011
  10. ncbi Identification of melanoma antigens using a Serological Proteome Approach (SERPA)
    Ayako Suzuki
    Shizuoka Cancer Center Research Institute, Nagaizumi cho, Sunto gun, Japan
    Cancer Genomics Proteomics 7:17-23. 2010

Collaborators

Detail Information

Publications23

  1. ncbi α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    BMC Cancer 12:623. 2012
    ..In the present study, we investigated the effect of activated dendritic cell (DC) (α-type-1 polarized DC)-based immunotherapy on high-grade glioma patients with the HLA-A2 or A24 genotype...
  2. ncbi Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka, 411 8777, Japan
    Cancer Immunol Immunother 61:2311-9. 2012
    ..Finally, we verified that the combination of the highly active DC-culture method and HLA-A24 peptide-docking simulation assay might be tools for predicting CTL epitopes against cancer antigens...
  3. ncbi Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Sunto gun, Shizuoka, Japan
    Oncol Rep 22:185-91. 2009
    ..The results showed that cloned CMV-specific TCR genes were efficient in reconstituting specific anti-CMV activity and might be good tools for adoptive immunotherapy against CMV infections...
  4. ncbi Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Anticancer Res 29:647-55. 2009
    ..Finally, successful identification of MAGE-1 A24 peptide-specific T-cell receptor (TCR) cDNA from anti-TCR MoAbsorted CTL was obtained for the first time and the specific cytotoxicity in TCR gene-transduced naive T-cells was confirmed...
  5. ncbi Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients
    Yasuto Akiyama
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Int J Oncol 33:433-41. 2008
    ..The results showed that cloned TCR cDNAs were efficient in reconstituting tumor-specific cytotoxicity and good candidates for novel immunotherapy...
  6. ncbi Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer
    Yasuto Akiyama
    National Cancer Center Research Institute, Growth Factor Division, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104, Japan
    Immunol Lett 95:199-205. 2004
    ..943, P<0.001). These results suggested that HLA-A*2402-CMVpp65 tetramer staining was an efficient way to monitor immune responses against CMV infection in HLA-A24+ immunocompromised hosts...
  7. ncbi Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail
    Yasuto Akiyama
    Growth Factor Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104, Japan
    Anticancer Res 24:571-7. 2004
    ..These results suggested that polyvalent immunotherapy using multiple epitopes from melanoma antigens might be a better way of improving the efficacy of treatment...
  8. ncbi Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
    Chie Oshita
    Division of Immunotherapy, Shizuoka Cancer Center Research Institute, Shizuoka 411 8777, Japan
    Oncol Rep 28:1131-8. 2012
    ..These results suggest that peptide cocktail-treated DC vaccines may be a safe and effective therapy against metastatic melanoma in terms of prolongation of overall survival time...
  9. ncbi Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients
    Akira Iizuka
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Immunol Lett 135:64-73. 2011
    ....
  10. ncbi Identification of melanoma antigens using a Serological Proteome Approach (SERPA)
    Ayako Suzuki
    Shizuoka Cancer Center Research Institute, Nagaizumi cho, Sunto gun, Japan
    Cancer Genomics Proteomics 7:17-23. 2010
    ..Melanoma is an intractable cancer with a poor prognosis and increasing prevalence worldwide. Specific biomarkers for early diagnosis have yet to be found...
  11. ncbi Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus
    Yasuto Akiyama
    Growth Factor Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104, Japan
    Immunol Lett 83:21-30. 2002
    ..These results suggested that the peptide (QYDPVAALF) is one of HLA-A24-restricted CTL epitope derived from CMV pp65 protein and may be of therapeutic value in peptide-based vaccines against CMV infection in BMT patients...
  12. ncbi Antitumor effect induced by dendritic cell (DC)-based immunotherapy against peritoneal dissemination of the hamster pancreatic cancer
    Yutaka Takigawa
    Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Lett 215:179-86. 2004
    ..These findings suggested that DC-based immunotherapy might be efficient for the treatment of peritoneal disseminations of the pancreatic cancer...
  13. ncbi Structure and characterization of hamster IL-12 p35 and p40
    Kouji Maruyama
    Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, 104-0045, Tokyo, Japan
    Mol Immunol 40:319-26. 2003
    ..These results suggest that the vectors containing hamster IL-12 cDNA might be suitable tools for developing an immunotherapeutic approach against experimental cancer in a hamster model...
  14. ncbi Changes in the expression of CD106, osteogenic genes, and transcription factors involved in the osteogenic differentiation of human bone marrow mesenchymal stem cells
    Feng Liu
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    J Bone Miner Metab 26:312-20. 2008
    ..The present study should help to provide a novel marker for isolating purified MSCs and characterizing osteogenic differentiation...
  15. ncbi Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells
    Yasuto Akiyama
    Growth Factor Division, National Cancer Center Research Institute, 5 1 1 Tsukuji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Oncol 21:509-14. 2002
    ..These results suggested that genetically modified CD34+ cell-derived DCs with human IL-12 gene are fully efficient in T cell priming, and could be a good tool for effective cancer immunotherapy...
  16. ncbi Hamster DEC-205, its primary structure, tissue and cellular distribution
    Kouji Maruyama
    Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
    Cancer Lett 181:223-32. 2002
    ..DEC-205 is a highly conserved molecule across the species suggesting its fundamental role in the immune system...
  17. ncbi Analysis of HLA-A24-restricted peptides of carcinoembryonic antigen using a novel structure-based peptide-HLA docking algorithm
    Yoji Nakamura
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka, Japan
    Cancer Sci 102:690-6. 2011
    ..These results suggested that our in silico assay system has potential advantages in efficiency of epitope prediction over BIMAS and ease of use for bioinformaticians...
  18. ncbi Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters
    Yasuto Akiyama
    Growth Factor Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Lett 184:37-47. 2002
    ..These findings suggest that DC-based immunotherapy may be a useful approach for the treatment of pancreatic cancers...
  19. ncbi Structure-function relationship of the nuclear localization signal sequence of parathyroid hormone-related protein
    Keiichic Ohshima
    Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka 411 8777, Japan
    Biomed Res 33:191-9. 2012
    ..We propose that PTHrP(97-107) is a useful carrier peptide for delivery and expression of cargo molecules in the cytoplasm...
  20. ncbi Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines
    Kazuki Sasaki
    Growth Factor Division, National Cancer Center Research Institute, Tokyo 104 0045, Japan
    Cancer Res 62:4894-8. 2002
    ..It is suggested that the peptide is generated inside the cells by limited proteolysis and extracellularly secreted. Our peptidomics-based approach will help screen candidate marker peptides for a particular type of cancer...
  21. ncbi Proteomic analysis of a highly metastatic gastric cancer cell line using two-dimensional differential gel electrophoresis
    Masako Takikawa
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka 411-8777, Japan
    Oncol Rep 16:705-11. 2006
    ..Moreover, these observations might be novel findings leading to the prediction of postoperative peritoneal recurrence...
  22. ncbi Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation
    Tadashi Ashizawa
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, Nagaizumi cho, Sunto gun, Shizuoka 411 8777, Japan
    Int J Oncol 38:1245-52. 2011
    ..Thus, STX-0119 may be a new type of STAT3 inhibitor exhibiting strong antitumor activity...
  23. ncbi CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies
    Yoji Nakamura
    Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi cho, Sunto gun, Shizuoka, 411 8777, Japan
    BMC Bioinformatics 11:398. 2010
    ..Therefore, we developed an integrated database of IG/TR data reported in cancer studies (the Cancer-related Immunological Gene Database [CIG-DB])...